White Paper: A new age in healthcare Enabling precision medicine by combining dose-optimized drug therapy with digital care

Enabling precision medicine by combining dose-optimized drug therapy with digital care

One size does not fit all when it comes to medicine

Improving outcomes for patients through tailored, personalized care

The traditional healthcare delivery model is struggling to support the management of medical conditions resulting in poorer outcomes for patients, higher healthcare costs for payors and lost value across the system.

At Closed Loop Medicine, we are improving drug effectiveness and patient outcomes through the development of a safe, protectable and scalable product solution that combines dose-optimized drug therapy with digital care.

  • Improving patient outcomes

    Providing integrated and personalized treatment solutions that support patients to monitor, track and improve their health

  • Reducing the cost of care

    Using technology to increase accessibility, optimize therapies and reduce healthcare delivery costs

  • Creating value across health systems

    Our unique platform enables the creation of new value based products

PIPELINE

A portfolio of next generation healthcare products

We have developed a patent protected and regulatory compliant platform for the creation of combination products that transform care; integrating drug therapy and digital therapeutics (DTx) to optimize therapy regimen, adherence and behavior change.

Platform & products

PARTNERSHIPS

Experienced approach supported by clinical evidence

We support pharmaceutical companies, payors and healthcare providers to improve the lives of patients with chronic disease through the creation of patent protected single prescription combination products.

Each product is individually tailored to disease use settings and built using our proprietary platform of intellectual property, regulatory expertise and clinical evidence.

Latest news

Press releases

Closed Loop Medicine appoints Paul Johnson as Non-Executive Director

Press releases

Closed Loop Medicine and Pharmanovia commence OptiZest study for their first precision medicine combination therapeutic

In the media

BioCentury’s latest podcast

Press releases

Closed Loop Medicine appoints Paul Johnson as Non-Executive Director

Press releases

Closed Loop Medicine and Pharmanovia commence OptiZest study for their first precision medicine combination therapeutic

In the media

BioCentury’s latest podcast

What they say about us

From the day of their first approach to us, we formed a close working relationship with the team from Closed Loop Medicine. The work has been stimulating. It’s all centered on finding the right treatment regime for each individual patient, centered on outcomes and personalized care.

Dr David Collier
Clinical Director, Queen Mary University London

CPI has core strengths in healthcare innovation and we were delighted to collaborate with Closed Loop Medicine on the next step towards more patient centric healthcare innovation, one that links traditional therapeutics, medical devices and digital health.

Arun Harish PhD MBA
Strategy Director, CPI

Closed Loop Medicine are pioneering the next generation of therapeutic products, one that links remote monitoring with intervention. At uMed we saw the potential to combine our unique approach to clinical trial delivery with Closed Loop Medicine to initiate an exciting decentralized clinical trial in partnership.

Matt Wilson
CEO, uMed

It has been refreshing to engage with the Closed Loop Medicine team. They proactively engaged the Association of Medical Research Charities early to encourage partnerships with research charities and involve patients in product and trial design.

Carol Bewick
Association of Medical Research Charities